Washiyama K - Search Results

1

Preliminary Evaluation of Astatine-211-Labeled Bombesin Derivatives for Targeted Alpha Therapy.

Aoki M, Zhao S, Takahashi K, Washiyama K, Ukon N, Tan C, Shimoyama S, Nishijima KI, Ogawa K. Aoki M, et al. Among authors: washiyama k. Chem Pharm Bull (Tokyo). 2020;68(6):538-545. doi: 10.1248/cpb.c20-00077. Chem Pharm Bull (Tokyo). 2020. PMID: 32475858 Free article.

2

alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.

Yoshimoto M, Ogawa K, Washiyama K, Shikano N, Mori H, Amano R, Kawai K. Yoshimoto M, et al. Among authors: washiyama k. Int J Cancer. 2008 Aug 1;123(3):709-15. doi: 10.1002/ijc.23575. Int J Cancer. 2008. PMID: 18498129

3

Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases.

Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y, Ueda M, Mori H, Saji H. Ogawa K, et al. Among authors: washiyama k. Nucl Med Biol. 2009 Feb;36(2):129-35. doi: 10.1016/j.nucmedbio.2008.11.007. Nucl Med Biol. 2009. PMID: 19217524

4

Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapy.

Ogawa K, Shiba K, Akhter N, Yoshimoto M, Washiyama K, Kinuya S, Kawai K, Mori H. Ogawa K, et al. Among authors: washiyama k. Cancer Sci. 2009 Nov;100(11):2188-92. doi: 10.1111/j.1349-7006.2009.01279.x. Epub 2009 Jul 10. Cancer Sci. 2009. PMID: 19659515 Free PMC article.

5

Bone target radiotracers for palliative therapy of bone metastases.

Ogawa K, Washiyama K. Ogawa K, et al. Among authors: washiyama k. Curr Med Chem. 2012;19(20):3290-300. doi: 10.2174/092986712801215865. Curr Med Chem. 2012. PMID: 22664247 Review.

6

Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy.

Ogawa K, Mizuno Y, Washiyama K, Shiba K, Takahashi N, Kozaka T, Watanabe S, Shinohara A, Odani A. Ogawa K, et al. Among authors: washiyama k. Nucl Med Biol. 2015 Nov;42(11):875-9. doi: 10.1016/j.nucmedbio.2015.07.001. Epub 2015 Jul 7. Nucl Med Biol. 2015. PMID: 26235266

7

Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using ²¹¹At-CXCR4 monoclonal antibody.

Oriuchi N, Aoki M, Ukon N, Washiyama K, Tan C, Shimoyama S, Nishijima KI, Takahashi K, Ito H, Ikezoe T, Zhao S. Oriuchi N, et al. Among authors: washiyama k. Sci Rep. 2020 Apr 22;10(1):6810. doi: 10.1038/s41598-020-63557-9. Sci Rep. 2020. PMID: 32321944 Free PMC article.

8

Thallium-201 Imaging in Intact Olfactory Sensory Neurons with Reduced Pre-Synaptic Inhibition In Vivo.

Shiga H, Wakabayashi H, Washiyama K, Noguchi T, Hiromasa T, Miyazono S, Kumai M, Ogawa K, Taki J, Kinuya S, Miwa T. Shiga H, et al. Among authors: washiyama k. Mol Neurobiol. 2020 Dec;57(12):4989-4999. doi: 10.1007/s12035-020-02078-y. Epub 2020 Aug 20. Mol Neurobiol. 2020. PMID: 32820461 Free PMC article.

9

Human dosimetry of free ²¹¹At and meta-[²¹¹At]astatobenzylguanidine (²¹¹At-MABG) estimated using preclinical biodistribution from normal mice.

Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S, Aoki M, Kubo H, Takahashi K, Ito H. Ukon N, et al. Among authors: washiyama k. EJNMMI Phys. 2020 Sep 22;7(1):58. doi: 10.1186/s40658-020-00326-7. EJNMMI Phys. 2020. PMID: 32960387 Free PMC article.

10

⁶⁸Ga- and ²¹¹At-Labeled RGD Peptides for Radiotheranostics with Multiradionuclides.

Ogawa K, Echigo H, Mishiro K, Hirata S, Washiyama K, Kitamura Y, Takahashi K, Shiba K, Kinuya S. Ogawa K, et al. Among authors: washiyama k. Mol Pharm. 2021 Sep 6;18(9):3553-3562. doi: 10.1021/acs.molpharmaceut.1c00460. Epub 2021 Aug 17. Mol Pharm. 2021. PMID: 34403257

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters